hnRNP A1 in RNA metabolism regulation and as a potential therapeutic target

Jianguo Feng, Jianlong Zhou, Yunxiao Lin, Wenhua HuangFrontiers in Pharmacology 2022 · DOI

Abstract

Abnormal RNA metabolism, regulated by various RNA binding proteins, can have functional consequences for multiple diseases. Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) is an important RNA binding protein, that regulates various RNA metabolic processes, including transcription, alternative splicing of pre-mRNA, translation, miRNA processing and mRNA stability. As a potent splicing factor, hnRNP A1 can regulate multiple splicing events, including itself, collaborating with other cooperative or antagonistical splicing factors by binding to splicing sites and regulatory elements in exons or introns. hnRNP A1 can modulate gene transcription by directly interacting with promoters or indirectly impacting Pol II activities. Moreover, by interacting with the internal ribosome entry site (IRES) or 3'-UTR of mRNAs, hnRNP A1 can affect mRNA translation. hnRNP A1 can alter the stability of mRNAs by binding to specific locations of 3'-UTR, miRNAs biogenesis and Nonsense-mediated mRNA decay (NMD) pathway. In this review, we conclude the selective sites where hnRNP A1 binds to RNA and DNA, and the co-regulatory factors that interact with hnRNP A1. Given the dysregulation of hnRNP A1 in diverse diseases, especially in cancers and neurodegeneration diseases, targeting hnRNP A1 for therapeutic treatment is extremely promising. Therefore, this review also provides the small-molecule drugs, biomedicines and novel strategies targeting hnRNP A1 for therapeutic purposes.

Introduction

RNA metabolism is a highly regulated traffic system where RNA-binding proteins (RBPs) act as the primary controllers, deciding the fate of every transcript. At the center of this system is hnRNP A1, one of the most abundant and versatile regulators in the cell. Often described as a "molecular Swiss Army knife," hnRNP A1 masterminds almost every stage of the RNA life cycle, from initial transcription to final decay. However, when its function is compromised—through overexpression in tumors or mutation in neurons—it disrupts cellular homeostasis, driving pathologies such as the "Warburg effect" in cancer or protein aggregation in neurodegenerative diseases.

Structural Architecture and Domain Mapping

The functional diversity of hnRNP A1 is rooted in its structural domains. The protein primarily consists of two N-terminal RNA recognition motifs (RRMs) and a C-terminal glycine-rich domain (GRD). The RRMs are responsible for high-affinity binding to specific RNA sequences, such as the UAGGGA/U motif identified through SELEX and CLIP-seq. The C-terminal domain contains an RGG box and the M9 nuclear localization signal, which facilitates its nucleocytoplasmic shuttling. Post-translational modifications, including phosphorylation, methylation, and poly(ADP-ribosylation), further modulate its activity and localization.

Domain structure and post-translational modification sites of hnRNP A1.

Regulatory Mechanisms in RNA Metabolism

The Splicing Tug-of-War

A critical aspect of hnRNP A1's function is its concentration-dependent competition with SR proteins (such as SRSF1). This "tug-of-war" determines alternative splicing outcomes; typically, hnRNP A1 promotes distal splice site selection or exon skipping, while SR proteins favor proximal sites. This balance is frequently altered in disease states to favor pathogenic isoforms.

Driving the Warburg Effect

hnRNP A1 plays a pivotal role in cancer metabolism by regulating the alternative splicing of the PKM gene. It binds to specific sites to favor the production of the PKM2 isoform over PKM1. Unlike PKM1, PKM2 promotes aerobic glycolysis, providing the metabolic building blocks necessary for rapid tumor proliferation and invasion.

Regulation of PKM alternative splicing by hnRNP A1 and its role in aerobic glycolysis.

Beyond Splicing: Translation and Stability

hnRNP A1 also functions as an IRES trans-acting factor (ITAF), binding to internal ribosome entry sites to initiate translation during cellular stress—a key survival mechanism for cancer cells. Additionally, it influences mRNA stability by binding to 3'-UTRs and participates in the biogenesis of circular RNAs (circRNAs) by facilitating "back-splicing" through the stabilization of intronic loops.

Therapeutic Landscape

Given its central role in disease, hnRNP A1 is a high-value therapeutic target. Current research is exploring several modalities:

  • Small Molecules: Compounds like VPC-80051 target the RNA-binding domain, while others like Quercetin trap the protein in the cytoplasm. Riluzole has shown efficacy in inhibiting its ITAF activity in glioblastoma.
  • Biopharmaceuticals: Antisense Oligonucleotides (ASOs) have successfully treated Spinal Muscular Atrophy (SMA) by blocking hnRNP A1 binding sites on the SMN2 gene to restore proper splicing.
  • Emerging Technologies: RNA-PROTACs represent a promising frontier, offering the ability to selectively degrade hnRNP A1 rather than merely inhibiting its binding.

Conclusion and Future Directions

While targeting hnRNP A1 holds great promise, significant challenges remain. The protein's high abundance and essential roles in healthy cells necessitate high specificity to avoid toxicity. Furthermore, delivering large molecules like ASOs or PROTACs across the blood-brain barrier for neurodegenerative conditions remains a hurdle. Future research must focus on precision targeting—developing therapies that disrupt specific disease-causing interactions without interfering with the protein's global homeostatic functions.

Summary updated

Abstract

Abnormal RNA metabolism, regulated by various RNA binding proteins, can have functional consequences for multiple diseases. Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) is an important RNA binding protein, that regulates various RNA metabolic processes, including transcription, alternative splicing of pre-mRNA, translation, miRNA processing and mRNA stability. As a potent splicing factor, hnRNP A1 can regulate multiple splicing events, including itself, collaborating with other cooperative or antagonistical splicing factors by binding to splicing sites and regulatory elements in exons or introns. hnRNP A1 can modulate gene transcription by directly interacting with promoters or indirectly impacting Pol II activities. Moreover, by interacting with the internal ribosome entry site (IRES) or 3'-UTR of mRNAs, hnRNP A1 can affect mRNA translation. hnRNP A1 can alter the stability of mRNAs by binding to specific locations of 3'-UTR, miRNAs biogenesis and Nonsense-mediated mRNA decay (NMD) pathway. In this review, we conclude the selective sites where hnRNP A1 binds to RNA and DNA, and the co-regulatory factors that interact with hnRNP A1. Given the dysregulation of hnRNP A1 in diverse diseases, especially in cancers and neurodegeneration diseases, targeting hnRNP A1 for therapeutic treatment is extremely promising. Therefore, this review also provides the small-molecule drugs, biomedicines and novel strategies targeting hnRNP A1 for therapeutic purposes.
BibTeX
@inproceedings{feng2022hnrnp,
  author = {Jianguo Feng and Jianlong Zhou and Yunxiao Lin and Wenhua Huang},
  title = {{hnRNP A1 in RNA metabolism regulation and as a potential therapeutic target}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.986409},
}
Figure